AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026, 6:00 AM ET Edesa Biotech and KYORIN Pharmaceutical agreed to develop and commercialize paridiprubart in Japan, with a $12 million upfront payment to Edesa. AI-generated summary · Source: company release
Nasdaq: $EDSAImmunology and dermatologyEB06 / CXCL10Clinical and financing risk

EDSA Stock Hub: Edesa Biotech News, EB06 and Vitiligo Development

Edesa licensed the Japanese rights to paridiprubart in ARDS to Kyorin Pharmaceutical for a $12 million upfront payment. The November 8 agreement adds up to $55 million in development and regulatory milestones, sales milestones of up to ¥12.0 billion and low double-digit tiered royalties; Edesa keeps the rights outside Japan and also gave notice to end its at-the-market agreement, effective November 16. EB06 U.S. recruitment is expected in Q1 2027 and topline in Q4 2027. The November 6 regular-session close was $2.14 (+0.47% versus November 5).

Last updated: November 9, 2026Market reference: November 6, 2026 regular-session closeFinancial period: June 30, 2026; subsequent offering closed August 21, 2026Archive research: October 16, 2026
Full research report · PDF
Edesa Biotech ($EDSA), research as of October 16, 2026
17 pages covering EB06 target biology and study design, paridiprubart evidence, daniluromer, cash, equity financing, licensing and dilution. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Get the report (PDF)
Next dated company event
November 16, 2026 · H.C. Wainwright at-the-market agreement termination takes effect

Edesa gave notice on November 8 of the termination of its At The Market Offering Agreement with H.C. Wainwright, effective November 16, according to its Form 8-K of November 9. Chief Executive Officer Par Nijhawan was scheduled to present a fireside chat on November 9 at 3:00 p.m. ET at Guggenheim’s 3rd Annual Healthcare Innovation Conference in Boston (November 9–11), where management is also due to hold one-on-one investor meetings. The company calendar also lists BIO Europe Fall in Cologne. Form 8-K · Conference announcement · Official events

On November 9 Edesa announced the Kyorin license for paridiprubart in Japan, with a $12 million upfront payment. Company release · The October 15 guidance targets U.S. EB06 enrollment in Q1 2027 and Phase 2 topline in Q4 2027. Canadian recruitment is underway. Clinical guidance
Edesa Biotech EDSA daily stock chart
Daily chart $EDSA. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

EDSA stock at a glance

Close · November 6, 2026
$2.14
Regular session; +0.47% versus $2.13 on November 5.
Cash · June 30
$10.333M
Historical cash before the August financing.
Operating cash use · nine months
$7.187M
Nine months ended June 30, 2026, not six months.
Completed August offering
About $25M gross
Closed August 21; fees and subsequent spending differ from gross proceeds.
Common shares · August 25
14.193M
Dated Schedule 13D/A basis, not fully diluted.
EB06 planned enrollment
Up to 80
Adults randomized 1:1 in the Phase 2 study.
EB06 primary endpoint
Week 28 F-VASI
Mean percentage change from baseline in facial disease measure.
Kyorin upfront payment
$12M
Non-refundable, payable under the November 8 license for paridiprubart in Japan; milestones are contingent.

Where Edesa Biotech stands now

EB06 is an investigational anti-CXCL10 antibody in a placebo-controlled vitiligo study. Clearance to expand the trial is separate from efficacy or approval. On November 8 Edesa granted Kyorin Pharmaceutical an exclusive license to develop and commercialize paridiprubart (EB05), its anti-TLR4 antibody, for acute respiratory distress syndrome in Japan: a one-time, non-refundable $12 million upfront payment, up to $55 million in development and regulatory milestones, sales milestones of up to ¥12.0 billion and low double-digit tiered royalties on Japanese net sales. The company puts the potential milestones at about $134 million in total. Kyorin funds development, regulatory and commercial work in Japan and has a right of first negotiation for acute kidney injury; Edesa keeps the rights outside Japan, including the United States, Europe and Canada, and will manufacture and supply the product. Paridiprubart itself is licensed to Edesa by NovImmune. The same day Edesa gave notice to terminate its October 2024 at-the-market agreement with H.C. Wainwright, effective November 16, 2026, without penalties. Form 8-K · Company release

Trial execution and financing still sit between clearance and a usable product. Recruitment, controlled benefit, safety, missing data and administration burden affect EB06. Paridiprubart exploratory analyses require prospective confirmation, and Kyorin milestone payments depend on development, regulatory and sales events in Japan. Equity awards, warrants, preferred instruments and future funding alter ownership; June going-concern language predates the August offering.

The constructive case

A completed financing, the $12 million Kyorin upfront payment and U.S. expansion can support controlled testing, while a Japanese partner now funds paridiprubart development in its territory. A meaningful benefit with acceptable safety could clarify next-stage development and partnering options.

The cautious case

Recruitment delays, weak efficacy, tolerability or higher costs can consume resources before revenue. Gross financing headlines say nothing about current cash or a dilution-free development path, and most of the Kyorin deal value depends on milestones that may never be reached, part of them in yen.

Latest Edesa Biotech news

Nov 9, 2026

Edesa Biotech announces agreement with KYORIN Pharmaceutical to develop and commercialize paridiprubart in Japan

Edesa Biotech and KYORIN Pharmaceutical entered an exclusive license agreement for paridiprubart in Japan for the treatment of ARDS. Edesa will receive an upfront payment of $12 million and milestones of up to approximately $134 million, a portion denominated in Japanese yen, plus tiered double-digit royalties on net sales in Japan. Kyorin will fund development and commercialization in Japan, and Edesa retains all rights outside Japan.

Nov 4, 2026

Edesa Biotech to present at Guggenheim Healthcare Innovation Conference

Edesa Biotech management will participate in Guggenheim's 3rd Annual Healthcare Innovation Conference, November 9–11, 2026, in Boston, Massachusetts. Participation includes a fireside chat on Monday, November 9, 2026, presented by CEO Par Nijhawan MD, and one-on-one investor meetings. Investors can arrange meetings through their Canaccord representative or at investors@edesabiotech.com.

Oct 29, 2026

CEO salary-related shares reported on Form 4

The filing records 27,602 fully vested restricted-share awards on October 28, replacing 90% of salary otherwise payable in cash for the specified retroactive period. Transaction code A denotes an award, not an open-market purchase.

Oct 23, 2026

Executive base salaries increased retroactively

The board raised CEO, president and CFO annual base salaries to $657,423, $591,681 and $525,938, respectively, retroactive to July 1. The CEO’s 90% monthly share-compensation arrangement continues.

Oct 15, 2026

FDA clearance permits U.S. EB06 study expansion

The ongoing Phase 2 vitiligo trial can expand into the United States. U.S. enrollment is expected next quarter, with Q4 2027 topline anticipated. Clearance is not efficacy evidence or approval.

Aug 19, 2026

Offering terms combine shares and warrants

The financing includes common shares, pre-funded warrants and accompanying common warrants. Potential exercise proceeds are distinct from the approximately $25M gross offering subsequently completed August 21.

EDSA stock catalysts: EB06 enrollment and the controlled readout

  • November 9, 2026 — Fireside chat at Guggenheim’s 3rd Annual Healthcare Innovation Conference in Boston, 3:00 p.m. ET. Scheduled event, November 9
  • November 16, 2026 — Termination of the H.C. Wainwright at-the-market agreement takes effect. Company notice of November 8
  • Q1 2027 — First U.S. EB06 sites expected to begin enrollment. Calendar interpretation of next-quarter guidance
  • Q4 2027 — EB06 topline anticipated. Company window, execution-dependent
  • Further development and financing — Regulatory planning, partnering and resources needed for later studies. No exact date established

EB06 study guidance · Guggenheim conference announcement · Kyorin license and ATM termination · Dated financial statements

EDSA EB06: mechanism, population and endpoint

The anti-CXCL10 rationale is distinct from repigmentation in patients. The study enrolls up to 80 adults with moderate-to-severe nonsegmental vitiligo, with treatment or placebo every two weeks through week 22 and a facial endpoint at week 28. The mean outcome, responder distribution, missingness, body measures and safety answer different questions.

EDSA cash, completed financing and ownership claims

The June cash balance and the completed August gross raise should not be added into a current-cash estimate. Fees, spending and working capital intervene. Pre-funded and common warrants, preferred shares and compensation awards affect ownership under different conditions. Licensed rights and contingent milestones also influence retained economics.

Merlintrader Health Score · $EDSA

2.80out of 5
Financial resources · 30%3.5

The completed August financing and the $12 million non-refundable Kyorin upfront payment due under the November 8 license, larger than the $7.2 million of operating cash used in the nine months to June 30, strengthen the historical June position; future trial costs remain material.

Catalysts · 30%3.0

A defined EB06 study and company windows provide milestones with the efficacy result still ahead; the Kyorin agreement adds contingent paridiprubart milestones in Japan.

Dilution and capital allocation · 20%2.5

Non-dilutive partner funding and the termination of the at-the-market agreement, effective November 16, reduce near-term issuance pressure; August securities, warrants, preferred instruments and awards still add potential ownership claims.

Trading liquidity · 10%1.0

The dated October 15 average-volume reference supports a cautious liquidity assessment; news can change trading sharply.

Operating execution · 10%2.5

A signed regional license with Kyorin and Canadian EB06 recruitment show progress; U.S. opening, manufacturing supply to Kyorin and controlled evidence remain execution tasks.

Assessed November 9, 2026, on the Kyorin license and ATM termination filing. Weighted calculation: 3.5×30% + 3.0×30% + 2.5×20% + 1.0×10% + 2.5×10% = 2.80. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

  • IND clearance is separate from clinical efficacy and marketing approval.
  • June going-concern language and cash figures predate the completed August financing.
  • Post hoc pooled analyses are hypothesis-generating rather than prospective validation.
  • Warrants, awards and licensed economics affect the amount retained per common share.
  • Only the $12 million Kyorin upfront payment is fixed; up to $55 million in development and regulatory milestones and up to ¥12.0 billion in sales milestones depend on events in Japan.

EDSA Stock FAQ: Edesa Biotech Questions Answered

What is the next EDSA stock catalyst?

Edesa expects U.S. enrollment in its EB06 Phase 2 vitiligo study next quarter, per its October 15, 2026 release, following recruitment already underway in Canada. Phase 2 topline results are anticipated in Q4 2027. Chief Executive Officer Par Nijhawan was scheduled to present a fireside chat at Guggenheim’s Healthcare Innovation Conference in Boston on November 9, 2026, at 3:00 p.m. ET, according to the company’s November 4 announcement; the ATM agreement termination takes effect on November 16, and BIO Europe Fall participation is also planned. EB06 enrollment and data guidance. Company events. Guggenheim fireside chat announcement.

Is Edesa’s EB06 FDA approved for vitiligo?

No: on October 15, 2026, Edesa announced FDA clearance of its IND application, permitting U.S. expansion of the EB06 Phase 2 vitiligo study. EB06 remains investigational. IND clearance allows clinical testing; it is not a determination that the treatment works or an authorization to market it. FDA IND clearance and study status.

How much cash does Edesa Biotech have?

Edesa held US$10,332,520 in cash and equivalents at June 30, 2026, before its August financing. Operating cash use was US$7,186,629 for the nine months ended June 30, 2026. That filing disclosed a material uncertainty casting substantial doubt on going concern. The later approximately US$25 million gross offering is not a current cash balance after fees and subsequent spending. Under the November 8 license, Kyorin will pay Edesa a one-time, non-refundable US$12 million upfront payment; it is not part of the June 30 balance. Kyorin upfront payment. June cash, nine-month cash flow and going concern. August financing terms.

Could EDSA stock be diluted by warrants or more shares?

Edesa’s prospectus filed August 20, 2026 offered 3,870,500 common shares, pre-funded warrants for 675,000 shares and accompanying common warrants for 4,545,500 shares. The common warrants carry a US$7.50 exercise price; future exercise proceeds are conditional. Additional equity issuance and compensation awards can also increase the share count. On November 8 Edesa gave notice to terminate its at-the-market agreement with H.C. Wainwright, effective November 16, 2026. ATM termination. Shares and warrant terms.

When does Edesa Biotech report earnings?

As of November 9, 2026, Edesa had not announced its next financial-results date. Its latest results release was August 13, 2026, covering fiscal Q3 ended June 30. Edesa’s fiscal year ends September 30, so its fiscal-quarter labels differ from calendar-year quarter labels. Financial-results announcements. Fiscal reporting calendar.

What does Edesa Biotech do?

As of October 15, 2026, Edesa is a clinical-stage biotechnology company developing treatments for inflammatory and immune-related diseases. EB06 targets CXCL10 and is in Phase 2 development for vitiligo. Its pipeline also includes paridiprubart for acute respiratory distress syndrome, whose Japanese rights were licensed to Kyorin Pharmaceutical on November 8, 2026 while Edesa keeps the rest of the world, and daniluromer, a Phase 3-ready dermatology asset. Kyorin agreement. Company and clinical pipeline.

When will Edesa report EB06 vitiligo trial results?

Edesa’s October 15, 2026 guidance anticipates EB06 Phase 2 topline in Q4 2027. The double-blind, placebo-controlled study plans up to 80 adults with moderate-to-severe nonsegmental vitiligo; its primary endpoint measures facial pigmentation change at Week 28. U.S. enrollment is expected in Q1 2027, without a specified first-patient date. Phase 2 design and topline guidance.

Did Edesa’s CEO buy shares in October 2026?

The October 28, 2026 transaction reported for Edesa CEO Pardeep Nijhawan was a grant of 27,602 fully vested restricted share units in lieu of salary. The Form 4 reports an award, rather than an open-market purchase. The compensation arrangement substitutes equity for part of his cash salary. CEO award and transaction footnote. Compensation arrangement.

Primary sources

Disclaimer. Educational and informational content only. This is not investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security. Readers are responsible for their own decisions and should consult a licensed financial adviser where appropriate. Clinical, regulatory, commercial and financing risks can cause substantial losses, including the loss of all invested capital. Readers remain responsible for their decisions.

AI-assisted content is reviewed against the sources cited, but errors remain possible. Company forecasts remain forecasts; interpretations are blog commentary. Some links, including the Finviz click-through, are affiliate links that may generate a commission at no additional cost to the reader. Legal information: disclaimer and terms and privacy.